Cooper Companies, Inc. (COO)

Several events have impacted The Cooper Companies' stock price in the past six months. Q3 2025 earnings revealed that CooperVision's organic growth fell short of expectations due to inventory challenges, and CooperSurgical experienced softness in fertility. Cooper Companies presented at the Wells Fargo Healthcare Conference. Insider buying was observed, and the company expanded its share repurchase program by $1 billion. Jana Partners acquired a position in the company, advocating for strategic alternatives. The company reported Q4 2025 earnings per share (EPS) of $1.15, surpassing analysts' expectations. Needham lowered its price target for COO due to potential competitive pressure, while William Blair resumed coverage with an "Outperform" rating. The stock closed lower as the broader medical device sector faced headwinds amid renewed AI disruption fears, despite positive institutional interest and the company's debt restructuring.

The Cooper Companies' quarterly results are generally expected to follow seasonal trends, with a lighter start to the fiscal year. Demand for premium brands like MyDay has been robust, but supply constraints have been a limiting factor. Softness in the fertility market was anticipated to persist through the fourth quarter of 2025, with expectations for a rebound in fiscal year 2026.

The Cooper Companies, Inc. operates through CooperVision and CooperSurgical. CooperVision focuses on contact lenses, including brands like MyDay, clariti, and Biofinity, addressing various vision challenges. CooperSurgical is dedicated to women's healthcare, providing medical devices, fertility products and services, surgical instruments, genomic testing, and contraceptive solutions.

The Cooper Companies, Inc. has a significant global presence, with products sold in over 100 countries. The company employs more than 15,000 individuals across 130 countries in Europe, Asia, Africa, and the Americas, with over half of its net sales generated from outside the United States.

The Cooper Companies maintains a strong brand reputation as a trusted leader in the contact lens industry and a leading fertility and women's healthcare company. Analyst sentiment has been notably bullish. The involvement of activist investor Jana Partners suggests a focus on optimizing company performance. The company also faces competitive pressures from other major players in the medical device sector.

The Cooper Companies, Inc. has significant institutional ownership, with 1175 institutional owners holding a total of 240,946,109 shares. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Capital World Investors. Mutual Funds & ETFs collectively hold 59.73% of the shares outstanding, while other institutional investors hold 40.27%. Individual investors hold approximately 0.6% of the shares.